89Zr-glofitamab

89Zr-glofitamab (89Zr-CED88004S) is a radiopharmaceutical imaging agent consisting of the CD20xCD3 bispecific antibody glofitamab labeled with the positron-emitting radioisotope zirconium-89 (89Zr). Developed by the Universitair Medisch Centrum Groningen in collaboration with Roche, it is utilized in positron emission tomography (PET) imaging to non-invasively assess the biodistribution, tumor targeting, and target occupancy of glofitamab in patients with B-cell malignancies, such as large B-cell lymphoma (LBCL). Glofitamab itself is a T-cell engaging bispecific antibody with a 2:1 molecular configuration (two CD20-binding sites and one CD3-binding site) designed to facilitate T-cell mediated cytotoxicity against malignant B cells. The radiolabeled version allows researchers to visualize the drug's interaction with the tumor microenvironment and optimize dosing strategies in clinical trials.

Other names

89Zr-labeled glofitamabzirconium Zr 89 glofitamab89Zr-DFO-glofitamab